Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Bracco Imaging spa, Via Egidio Folli 50, 20134, Milano Italy
Pharmacotherapeutic group; ATC code: V08AB04
Iopamidol is contrast medium belonging to the new generation of non-ionic compound whose solubility is due to the presence of hydrophilic substitutes in the molecule. This results in a solution of low osmollity when compared with ionic media.
Iopamidol has been shown to be effective as an X-ray contrast medium in neuroradiology, angiography, venography, arthrography, urography, cerebral angiography and left ventriculography and coronary arteriography. Its toxicity particularly cardiac and CNS toxicity are less than those of ionic contrast media.
The pharmacokinetics of iopamidol conform to an open two compartment pharmacokinetic model with first order elimination.
Distribution volume is equivalent to extracellular fluid.
Elimination is almost completely through the kidneys. Less than 1% of the administered dose has been recovered in the faeces up to 72 hours after dosing. Elimination is rapid; up to half the administered dose may be recovered in the urine in the first two hours of dosing.
There is no evidence of biotransformation. Serum protein binding is negligible.
No adverse effects can be predicted from animal toxicology studies other than those documented from human use of iopamidol.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
